12 completed. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 12 |
Follow Communication Disorders: new trials by email Literature Review of Communication Disorders trials Research Report on Communication Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Motor Tasks and Lidocaine on Reading Unfamiliar Words in Adults With and Without Dyslexia Lidocaine 2% Polyampoule - Reading Disorders | Phase 4 | Completed | University of Alberta | 56 | 2023-08-24 | 2026-02-05 |
| Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine - Non-verbal Learning Disorder, Autism Spectrum Disorder | Phase 4 | Completed | Massachusetts General Hospital | 54 | 2019-05-20 | 2025-06-05 |
| A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Dexmedetomidine bolus and high infusion-Propofol, Dexmedetomidine bolus and low infusion-Propofol, Dexmedetomidine bolus only - Propofol - Epilepsy, Cerebral Palsy | Phase 4 | Completed | Joseph Cravero | 71 | 2017-03-02 | 2023-06-27 |
| Interventions for Children With Attention and Reading Disorders Methylphenidate, Intensive reading instruction, Parent Training - Attention Deficit Hyperactivity Disorder, Reading Disabilities | Phase 4 | Completed | The University of Texas Health Science Center, Houston | 222 | 2010-11-01 | 2017-04-11 |
| Effects of Virtual Reality System in Children With Developmental Delays virtual reality system - Developmental Delays | Phase 4 | Completed | Ru-Lan Hsieh | 157 | 2009-01-01 | 2014-07-09 |
| Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Dyslexia | Phase 4 | Completed | Eli Lilly and Company | 110 | 2008-09-01 | 2022-11-04 |
| Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Dyslexia | Phase 4 | Completed | Eli Lilly and Company | 209 | 2008-03-01 | 2011-12-15 |
| Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population Swallow instruction - Epilepsy, Mental Retardation | Phase 4 | Completed | Children's National Research Institute | 20 | 2005-08-01 | 2008-05-05 |
| Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) Atomoxetine Hydrochloride, placebo - Attention Deficit Hyperactivity Disorder, Reading Disorder | Phase 4 | Completed | Eli Lilly and Company | 121 | 2005-04-01 | 2010-05-25 |
| Memantine and Intensive Speech-Language Therapy in Aphasia memantine, constraint-induced language therapy (CIAT), placebo - Aphasia, Stroke | Phase 4 | Completed | Gabinete Berthier y Martínez | 28 | 2005-03-01 | 2008-03-21 |
| Dopaminergic Enhancement of Learning and Memory in Aphasia levodopa - Cerebrovascular Accident, Aphasia | Phase 4 | Completed | University Hospital Muenster | 12 | 2005-01-01 | 2013-10-07 |
| Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Donepezil - Stroke, Aphasia | Phase 4 | Completed | Gabinete Berthier y Martínez | 30 | 2003-02-01 | 2005-09-20 |
Dyslexia (5) · Attention Deficit Disorder with Hyperactivity (4) · Learning Disabilities (4) · Aphasia (3) · Stroke (3) · Epilepsy (2) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Cerebral Palsy (1) · Developmental Disabilities (1) · Intellectual Disability (1) · Seizures (1)
Nervous System Diseases (12) · Neurobehavioral Manifestations (12) · Neurologic Manifestations (12) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Mental Disorders (9) · Neurodevelopmental Disorders (9) · Language Disorders (8) · Brain Diseases (5) · Central Nervous System Diseases (5) · Learning Disabilities (5) · Specific Learning Disorder (5) · Attention Deficit and Disruptive Behavior Disorders (4) · Cardiovascular Diseases (3)
Atomoxetine Hydrochloride (4) · Acetylcysteine (1) · Donepezil (1) · Fatty Acids, Omega-3 (1) · Guanfacine (1) · Inositol (1) · Levodopa (1) · Lidocaine (1) · Memantine (1) · Methylphenidate (1)
Eli Lilly and Company (3) · Gabinete Berthier y Martínez (2) · Children's National Research Institute (1) · Joseph Cravero (1) · Massachusetts General Hospital (1) · Ru-Lan Hsieh (1) · The University of Texas Health Science Center, Houston (1) · University Hospital Muenster (1) · University of Alberta (1)
United States (6) · Spain (2) · Belgium (1) · Canada (1) · Germany (1) · Netherlands (1) · Taiwan (1)
Carolyn A Denton, Ph.D. (1) · Caterina Breitenstein, PhD (1) · Janet Wozniak, MD (1) · Joan A Conry, MD (1) · Joseph Cravero, MD (1) · Marcelo L. Berthier, M.D., Ph.D (1) · Marcelo L. Berthier, M.D., Ph.D. (1) · Ru-Lan Hsieh, MD (1) · Stefan Knecht, MD (1)
PMID 25019647, PMID 20035588, PMID 24206099, PMID 25588456, PMID 26983099, PMID 27410907, PMID 27845858, PMID 33772416, PMID 42179727
2019 (1), R01HD060617 (1)